EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Vitamin A and/or high-dose Ara-C in the maintenance of remission in acute myelogenous leukaemia in children?


Scandinavian Journal of Haematology 33(3): 256-259
Vitamin A and/or high-dose Ara-C in the maintenance of remission in acute myelogenous leukaemia in children?
8 children with acute myelogenous leukaemia were brought into remission with a induction regimen containing cytosin arabinoside (Ara-C), 6-thioguanine and adriamycin given as the DNA complex. After remissions were obtained, the children were consolidated with high-dose Ara-C (2 g/m2 every 12 h for 6 doses) and were given 50 000 IU of vitamin A daily as an inducer of differentiation. All children are in continuous relapse-free survival for periods of 5 to 29 months (mean 14 months).

Accession: 001507954

PMID: 6594739

DOI: 10.1111/j.1600-0609.1984.tb02225.x

Download PDF Full Text: Vitamin A and/or high-dose Ara-C in the maintenance of remission in acute myelogenous leukaemia in children?



Related references

Vitamin A and/or high-dose Ara-C in the maintenance of remission in acute myelogenous leukaemia in children?. Scandinavian Journal of Haematology 33(3): 256-259, 1984

Vitamin a and or high dose cytosine arabinoside in the maintenance of remission in acute myelogenous leukemia in children. Scandinavian Journal of Haematology 33(3): 256-259, 1984

High-dose cytosine arabinoside remission induction for acute myelogenous leukemia: comparison of two regimens of remission maintenance. Leukemia 6(11): 1192-1198, 1992

Maintenance of remission in acute myelogenous leukaemia by a mixture of B.C.G. and irradiated leukaemia cells. Lancet 2(8048): 1107-1110, 1977

High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia. Annals of Oncology 11(8): 1007-1015, 2000

High-dose treatment with peripheral blood progenitor cell support as consolidation of first remission in younger patients with acute myelogenous leukaemia. Blood 92(10 SUPPL 1 PART 1-2): 293A, Nov 15, 1998

Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. British Journal of Haematology 92(3): 620-626, 1996

High-dose retinol in children with acute myelogenous leukemia in remission. European Journal of Haematology 40(5): 460-465, 1988

Chemotherapy and corynebacterium parvum for induction and maintenance of remission in acute myelogenous leukaemia--a controlled study. Indian Journal of Cancer 20(2): 119-123, 1983

Low dose-rate irradiation in the treatment of acute myelogenous leukaemia in first remission. Radiography 47(556): 101-104, 1981